CLOSE

Benchmark Investments

ITI Pharma & Healthcare Fund-Reg(G)

very highequitypharma & health care
16.19 0.07(0.43%) NAV as on 26 Jun 2025
1.15 % 1 M
16.14 % 1 Y
23.23 % 3 Y

Growth Chart of the Scheme vis a vis benchmark

  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 3Y
  • 5Y
  • 10Y

SCHEME DETAILS

Expenses Ratio :

2.35

As on 31 May, 2025
Age :

3 yrs 7 m

Since 08 11 ,2021
Exit Load :

0.5%

AUM :

220.85 Crs

Portfolio Price To Book Value :

8.56

Investing Style :

Large Growth

Min. Investment :

SIP 500 & Lumpsum 5000

Category :

sector funds

Fund Manager :

Rohan Korde,Dhimant Shah

Launch Date :

08-Nov-21

Scheme Benchmark :

NA

FUND OBJECTIVE

The investment objective of the scheme is to seek to generate long term capital appreciation throughinvesting in equity and equity related securities of companies engaged in Pharma and Healthcare.However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.

RISKOMETER Level of Risk in the Scheme

Investors understand that their principal will be at very high risk

LATEST ASSET & PORTFOLIO ALLOCATION

as on May 31 ,2025
Others 0.29 %
Equity 99.71 %

TOP HOLDINGS

Sun Pharmaceutical Industries...15.18 %
Divi's Laboratories Ltd.9.12 %
Max Healthcare Institute Ltd.5.42 %
Lupin Ltd.5.40 %
Apollo Hospitals Enterprise Ltd.5.19 %
See All Holding

ALLOCATION BY MARKET CAP

ALLOCATION BY SECTOR

Pharmaceuticals & Drugs73.61
Hospital & Healthcare Services20.25
Pesticides & Agrochemicals2.56
Business Support1.29
Industrial Gases & Fuels1.07
See All Sectors

5-YEARS HISTORY

Financial Year2021-20222022-20232023-20242024-2025
NAV in Rs (as on 31-Mar-2025)9.528.9413.5315.64
Net Assets(Rs Crores) (as on 31-Mar-2025) 175.15 135.04 160.39 213.78
Scheme Returns(%)(Absolute)-4.83-6.0951.0514.23
B'mark Returns(%)(Absolute)NANANANA
Category Rank74/7564/7629/9013/102

Quarterly Performance - Last 5 Years (Absolute Ret. In %)

Financial Year Q1 Q2 Q3 Q4
2024-20254.5219.842.86-10.24
2023-202414.798.1111.209.63
2022-2023-9.488.780.04-4.62
2021-2022NANANA-7.30

PERFORMANCE COMPARISON WITH SIMILAR SCHEMES

ITI Pharma & Healthcare Fund-Reg(G)Very HighEquity16.190.07(0.43%)NAV As on 26 Jun, 202508-Nov-2021Inception Date220.85AUM In Cr.16.14%1Y23.23%3YNA%5Y14.19%Since Inception
ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund-(G)Very HighEquity39.03-0.05(-0.13%)NAV As on 26 Jun, 202513-Jul-2018Inception Date5,507.52AUM In Cr.22.01%1Y29.41%3Y24.24%5Y21.61%Since Inception
SBI Healthcare Opp Fund-Reg(G)Very HighEquity422.254.45(1.07%)NAV As on 26 Jun, 202514-Jul-1999Inception Date3,689.28AUM In Cr.19.22%1Y28.26%3Y23.31%5Y16.24%Since Inception
Nippon India Pharma Fund(G)Very HighEquity512.421.33(0.26%)NAV As on 26 Jun, 202505-Jun-2004Inception Date8,352.16AUM In Cr.15.60%1Y25.14%3Y21.80%5Y20.54%Since Inception

BENCHMARK INVESTMENTS

Benchmark Investments, 6 Sector II Shanti Niketan, Govindpura Bhopal, Bhopal-462023, India. +91-755-4938282/+91-9826310337 hello@benchmarkinvestments.in.
Downloads
Quick Links
Useful Links

Mutual fund and other investments are always subject to market risks. Please read all, Scheme Information Documents (SID), Key Information Memorandum (KIM), Addendums(if any) issued there to from time to time and any other related documents or information carefully before investing. Past performance is not indicative or assurance of future performance or returns. Please consider your specific investment requirements before choosing a fund.

For any grievances, investors can contact at: hello@benchmarkinvestments.in,  Tel: +91-755-4938282 / +91-9826310337.
©  Copyrights 2022 , Benchmark Investments | All Rights Reserved |  Designed, Developed & Content Powered by Accord Fintech Pvt Ltd